In addition to β amyloid targets, the new drug pipeline for Alzheimer's disease is booming

Currently, three advanced drugs to treat Alzheimer's disease dominate the headlines in the field: Eisai and Bojian's Lecanemab, Genentech's Gantenerumab and Eli Lilly's donanemab

A new study by the Alzheimer's Disease Association (AA), scraped from a ClinicalTrials.

Therapies that try to truly change the disease account for 83 percent of drug candidates, and biopharmaceutical companies sponsor half of all trials and 68 percent of late-stage studies

Phase 3

In addition to lecanemab, gantenerumab and donanemab (all in the late stages of development and key readings expected to be released next year), the first thing worth noting is Cassava Sciences' simufilam, which is conducting two Phase 3 studies with completion dates of October 2023 and June

Quince Therapeutics' atuzaginstat is in late-stage trials with an expected end date of December

Novo Nordisk's semaglutide, under the trade name Ozepic, was approved for use in diabetes and weight management

Phase 2

The UCB Pharma2 project bepranemab (target tau protein), which is being studied in patients with mild cognitive impairment or mild Alzheimer's disease, is expected to end in November

AC Immune and Janssen are also betting on the TAU target, and the ACI-35 study they developed is nearing completion with an end date of October

Athira Pharma's fosgonimeton in three interim studies ended in October

Phase 1

Eli Lilly's LY3372993 (remternetug) is known as the "next generation of anti-β amyloid antibodies

After bohai and eisai material's Aduhelm was approved in the summer of 2021, Acumen Pharmaceuticals immediately rode the storm and raised $160 million in funding